• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Advances in pharmacology applied to maxillofacial anaesthesia
 

Advances in pharmacology applied to maxillofacial anaesthesia

on

  • 2,626 views

 

Statistics

Views

Total Views
2,626
Views on SlideShare
2,582
Embed Views
44

Actions

Likes
1
Downloads
52
Comments
0

7 Embeds 44

http://hi-dentfinishingschool.blogspot.com 24
http://www.slideshare.net 9
http://hi-dentfinishingschool.blogspot.in 6
http://hi-dentfinishingschool.blogspot.ca 2
http://www.hi-dentfinishingschool.blogspot.com 1
http://www.hi-dentfinishingschool.blogspot.in 1
http://hi-dentfinishingschool.blogspot.com.au 1
More...

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Advances in pharmacology applied to maxillofacial anaesthesia Advances in pharmacology applied to maxillofacial anaesthesia Presentation Transcript

    • Advances in pharmacology applied to maxillofacial anaesthesia
      • Postoperative nausea and vomiting (PONV) and Anti-emetics
      • Pain and Analgesics
      • Future developments
    • PONV
      • Incidence approximately 25%, (5-75%)
      • Medical impact minor
      • Patient’s impact HUGE
      • Requires treatment
    • PONV
      • Patient characteristics
      • Female>male (x3). Incidence increases during menstruation and decreases after the menopause. after 70 years of age,both sexes are equally affected. Obese (has been suggested, although there is currently insufficient evidence to conclude an association). Young. Risk of PONV is almost twice that for adults. Equal distribution between boys and girls until puberty. Previous history of PONV/motion sickness Early ambulation, early postoperative eating and drinking.
      • Surgery Intra-abdominal-laparoscopic Intracranial, middle ear Squint surgery (highest incidence of PONV in children) Gynaecological, especially ovarian Head and neck, especially tonsillectomy and adenoidectomy (suggested due to blood in upper gastrointestinal tract (GIT), stimulation of trigeminal nerve afferents and peroperative opioids). Prolonged surgery Painful
      • Anaesthesia/drugs Opioids (NB untreated pain is also emetogenic) Sympathomimetics Inhalational agents (Isoflurane++) Etomidate, ketamine, methohexitone (compared with propofol and thiopentone) Neostigmine (recent work suggests that this is not associated with PONV) Nitrous oxide (GIT distension/expansion of middle ear cavities). Prolonged anaesthesia Spinal anaesthesia (blocks above T5), hypotension. Intraoperative dehydration Inexperienced bag and mask ventilation (gastric dilatation).
      • Intercurrent Disease Intestinal obstruction Metabolic, e.g. hypoglycaemia, uraemia Hypoxia
    • PONV
    • PONV
      • Tramèr MR . A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand. 2001 Jan;45(1):4-13.
      • Tramèr MR . A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anaesthesiol Scand. 2001 Jan;45(1):14-9 .
      • Tramèr MR. (Editorial) Rational control of PONV – the rule of three/Le contrôle rationnel des NVPO – la règle de trios. Canadian Journal of Anesthesia. 2004 51:283-285
    • PONV
      • 1. Reduce the baseline risk by such measures as reducing nitrous oxide use, avoiding neostigmine, using local anaesthetics wherever possible instead of opiates and using propofol for induction and maintenance of anaesthesia.
      • 2. Do not use routine preventative treatment as it does not work well, is less cost effective and unnecessarily exposes patients to the drugs.
      • 3. Identify the high risk patients and then use an effective drug combination.
    • PONV
      • Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1990; 91:693-700.
      • Koivuranta M, Läärä E, Snare L, Alahunta S. A survey of postoperative nausea and vomiting.
      • Anesthesia. 1997; 52:443-449.
    • PONV
      • Major Proven Risk factors
      • Female gender
      • P/H of PONV or motion sickness
      • Non smokers
      • Opiates
      • Surgery duration >60 mins
    • PONV
      • Cumulative risk % Apfel Koivuranta
      • Background risk 10 17
      • Plus 1 risk factor 21 18
      • 2 39 42
          • 3 61 54
          • 4 79 74
          • 5 87
    • PONV
      • Major Proven Risk factors
      • Female gender
      • P/H of PONV or motion sickness
      • Non smokers
      • Opiates
      • Surgery duration >60 mins
    • PONV
      • For an effective drug combination:
      • It has been shown that both dexamethasone and droperidol increase the efficacy of “setrons” and it is more effective to give a “cocktail” of prophylaxis.
      • For example: steroid (dexamethasone 8mg) at induction and a 5-HT3 antagonist, good for treating vomiting, (ondansetron 4mg) with a D2 antagonist, good for treating nausea, (droperidol 0.75mg) at the end of the procedure .
      • There is no evidence for an effect greater than placebo for metoclopramide.
    • PONV
      • Conclusion 1
      • MORE IS BETTER !
      • Prospective randomized, double-blind comparative study of dexamethasone, ondansetron, and ondansetron plus dexamethasone as prophylactic antiemetic therapy in patients undergoing day-case gynaecological surgery. Thomas R, Jones N. Br J Anaesth 2001; 87(4): 588-92 .
      • Prevention of vomiting after strabismus surgery in children: dexamethasone alone versus dexamethasone plus low-dose ondansetron. Splinter WM. Paediatr Anaesth 2001; 11(5): 591-5 .
    • PONV
      • Conclusion 2
      • “ The best ‘setron’ is the cheapest ‘setron’. “
      • (Remember oral formulations are available)
    • ANALGESICS
      • Williams DG , Patel A , Howard RF .
      • Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth. 2002 Dec;89(6):839-45.
    • ANALGESICS
      • Codeine analgesia is wholly or mostly due to its metabolism to morphine by the cytochrome P450 enzyme CYP2D6
      • Forty-seven per cent of children had genotypes associated with reduced enzyme activity.
      • Morphine and its metabolites were not detected in 36% of children given codeine
    • ANALGESICS
      • Intra-venous paracetamol
      • PERFALGAN ® Bristol-Meyers Squibb
      • 1gm infusion equivalent to 10mg Morphine IMI
    • ANALGESICS
      • Tramadol
      • Karen Kaye ,
      • Executive Officer, NSW Therapeutic Advisory Group (formerly NSW Therapeutic Assessment Group), Sydney
      • Trouble with tramadol
      • Key words: analgesia, drug interactions, serotonin.
      • Aust Prescr 2004;27:26–7
    • ANALGESICS
      • As of March 2004 the Australian Adverse Drug Reactions Advisory Committee (ADRAC) has received 726 reports of adverse events associated with tramadol, detailing 1922 reactions
      • Nausea, vomiting, dizziness, confusion and seizures. The potential for serious drug-drug interactions should not be underestimated.
      • Like codeine, tramadol is metabolised via the CYP2D6 isoenzyme of cytochrome P450 to an active metabolite which binds to µ receptors
      • For most patients, a combination of paracetamol and codeine will be equally effective and possibly better tolerated than tramadol
    • ANALGESICS
      • COX 2 Inhibitors
    • ANALGESICS
      • COX2 inhibitors
      • can also increase blood pressure, induce or worsen cardiac failure and impair kidney function to the point of renal failure
      • but, no significant effect on platelets or bleeding time, no opioid side effects and highly rated by the patients
    • ANALGESICS
      • PARECOXIB, DYNASTSAT ® Pharmacia
      • in combination with morphine provides significant opioid-sparing effects
      • improved pain management and patient satisfaction, in two major surgical pain models, compared with morphine alone.
      • T. Philip Malan, Jr, MD, PhD, Stephen Gordon, MD , Richard Hubbard, MD , and Michael Snabes, MD
      • The Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium Is as Effective as 12 mg of Morphine Administered Intramuscularly for Treating Pain After Gynecologic Laparotomy Surgery
      • Anesth Analg 2005;100:454-460
    • ANALGESICS
      • Chemical structure of remifentanil
    • ANALGESICS
      • C.-S. Degoute, M.-J. Ray, M. Manchon, C. Dubreuil, and V. Banssillon
      • Remifentanil and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty Can J Anesth, January 1, 2001; 48(1): 20 - 27.
      • Caverni, Valentina PhD; Rosa, Giovanni; Pinto, Giovanni; Tordiglione, Paolo PhD; Favaro, Roberto
      • Hypotensive Anesthesia and Recovery of Cognitive Function in Long-term Craniofacial Surgery.
      • Journal of Craniofacial Surgery. 16(4):531-536, July 2005 .
    • THE FUTURE
      • Org 25969
    • THE FUTURE
      • Fentanyl PCTS
      • Iontophoretic patient controlled transdermal system
    • THE FUTURE
      • ACRUX
      • Analgesics, anxiolytics, antiemetics
      • (Competing Interests: Shareholder)
    • THE FUTURE
      • New antiemetics
      • Antineurokinins AntiNK1
      • Cannabinoids Nabilone
    • The Future
      • “… a safe substitute for propofol,with many propofol like properties, is expected to be approved by the FDA for non-anesthesiologists ’ use in the next year or two.”
    • THE FUTURE
      • Fechner, Jorg M.D. ; Ihmsen, Harald Ph.D. ; Hatterscheid, Dirk M.D. ; Jeleazcov, Christian M.D. ; Schiessl, Christine M.D. ; Vornov, James J. M.D., Ph.D. ; Schwilden, Helmut M.D., Ph.D.; Schuttler, Jurgen M.D.
      • Comparative Pharmacokinetics and Pharmacodynamics of the New Propofol Prodrug GPI 15715 and Propofol Emulsion.
      • Anesthesiology. 101(3):626-639, September 2004.
      • THE END